Replication competent La Crosse virus pseudotyped VSV vector system as vaccine and serological diagnostic reagent
Open Access
- 15 December 2025
- journal article
- Published by Elsevier in Virus Research
- Vol. 363, 199676
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institutes of Health National Cancer Institute (R01 CA258239)
This publication has 39 references indexed in Scilit:
- Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, GabonJournal of Infection, 2024
- Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 OmicronCell, 2022
- Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2Journal of Immunological Methods, 2021
- Live Attenuated Measles Virus Vaccine Expressing Helicobacter pylori Heat Shock Protein AMolecular Therapy-Oncolytics, 2020
- Zika virus: lessons learned in BrazilMicrobes and Infection, 2018
- Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectorsVaccine, 2012
- La Crosse virus (LACV) Gc fusion peptide mutants have impaired growth and fusion phenotypes, but remain neurotoxicVirology, 2010
- Role of La Crosse virus glycoproteins in attachment of virus to host cellsVirology, 1991
- Genetic determinants of the virulence and infectivity of La Crosse virusMicrobial Pathogenesis, 1988
- Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoproteinVirology, 1984